45 Results for 'Toxicology'
A broad strategy to reduce the toxicity of protein drugs
Therapeutic variants of the natural hormone erythropoietin (EPO) which is produced in the kidney to boost the production of red blood cells are commonly used to treat anemias stemming from kidney disease, chemotherapy and other complications. However, many drugs that are based on therapeutic proteins, including EPO, often cause unwanted side effects because they not...
Pathogen Capture Technology for Infectious Disease Therapeutics and Diagnostics
Microbial contamination is the cause of life-threatening cases of sepsis, meningitis and multiple other infectious diseases that are a major cause of death world-wide. Equally prevalent are pathogenic contaminants in our environment, food, and manufacturing processes. In each case, the presence of microbial contaminants must be confirmed, and when they are found, they need to...
Clinical studies take years to complete and testing a single compound can cost more than $2 billion. Meanwhile, innumerable animal lives are lost, and the process often fails to predict human responses because traditional animal models often do not accurately mimic human pathophysiology. For these reasons, there is a broad need for alternative ways to...
Video/Animation3D Printed Heart-on-a-ChipIn this video, learn how Wyss Institute and Harvard SEAS researchers have created a 3D-printed heart-on-a-chip that could lead to new customizable devices for short-term and long-term in vitro testing. Credit: Johan U. Lind (Disease Biophysics Group), Alex D. Valentine and Lori K. Sanders (Lewis Lab)/Harvard University
Video/AnimationBioprinting: The Kidney’s Proximal TubulesIn this video, see how the Wyss Institute team has advanced bioprinting to the point of being able to fabricate a functional subunit of a kidney. Credit: Wyss Institute at Harvard University
Video/AnimationBioinspired Approach to Sepsis TherapyWyss Institute Founding Director Don Ingber, Senior Staff Scientist Michael Super and Technology Development Fellow Joo Kang explain how they engineered the Mannose-binding lectin (MBL) protein to bind to a wide range of sepsis-causing pathogens and then safely remove the pathogens from the bloodstream using a novel microfluidic spleen-like device. For more information, please visit...